What is Holobiome?
Holobiome is a biotechnology firm at the forefront of discovering and developing first-in-class therapies originating from the human microbiome. Leveraging cutting-edge scientific insights, the company focuses on creating innovative probiotics and targeted health solutions aimed at promoting comprehensive whole-body wellness. Established by research scientists from Northeastern University, Holobiome is committed to addressing complex medical challenges by harnessing the therapeutic potential of gut microbes. Their core mission revolves around enhancing global health through the exploration and application of microbiome-derived treatments.
How much funding has Holobiome raised?
Holobiome has raised a total of $99K across 1 funding round:
Debt
$99K
Debt (2021): $99K with participation from PPP
Key Investors in Holobiome
PPP
Public-Private Partnership
What's next for Holobiome?
With substantial backing at a significant Series B/C stage, Holobiome is strategically positioned for accelerated growth and the advancement of its therapeutic pipeline. The company's focus on translating microbiome research into tangible health solutions suggests a trajectory towards clinical development and potential market entry. Future endeavors will likely involve expanding research and development capabilities, forging strategic partnerships, and navigating the regulatory landscape to bring its innovative probiotic and targeted therapies to patients. The continued investment signals strong confidence in Holobiome's scientific approach and its potential to revolutionize treatments for a range of health conditions.
See full Holobiome company page
